Abstract
Aim: Tumor necrosis factor inhibitors (TNFi) are widely used for the treatment of autoimmune diseases, with latent tuberculosis infection (LTBI) reactivation being a significant unresolved issue. The pathogenic mechanisms are not fully understood. Integrated transcriptomic analysis could provide insights into monitoring tuberculosis progression after TNFi therapy and help reduce LTBI reactivation. Methods: We selected six transcriptomic datasets from studies related to TNFi treatment and tuberculosis. Pathway enrichment, pseudotime, and transcription factor analyses were performed to explore the underlying mechanisms. Results: Our analysis revealed distinct transcriptional changes in memory B cells during tuberculosis progression and TNFi therapy. In active tuberculosis (ATB), ROR1 + memory B cells were identified in a noncanonical differentiation trajectory, characterized by downregulation of B cell‐related genes (e.g., CD22, EBF1, MS4A1), reduced translational capacity, and suppression of immune response pathways, accompanied by upregulation of oxidative phosphorylation, which highlighted metabolic alterations during tuberculosis progression. A similar subtype also emerged in TNFi‐treated patients, suggesting that metabolic reprogramming of memory B cells may disrupt immune balance, thereby contributing to LTBI reactivation and ATB development following TNFi therapy. Conclusions: The study integrates bioinformatics and single‐cell RNA sequencing to reveal the role of memory B cells in ATB progression and TNFi treatment, offering insights into TNFi‐associated TB susceptibility and potential therapeutic targets.
Funding Information
  • Guangdong Provincial Applied Science and Technology Research and Development Program

This publication has 40 references indexed in Scilit: